DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate
(DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately
severe Pneumocystis pneumonia (PCP).
Phase:
Phase 3
Details
Lead Sponsor:
Immtech Pharmaceuticals, Inc
Treatments:
Maleic acid Pafuramidine Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination